📃 Background: The Product and Original Protocol

The subject of this case study is a film-coated immediate-release tablet containing a highly stable API. The initial stability protocol included long-term storage at 25°C/60%RH, intermediate storage at 30°C/65%RH, and accelerated storage at 40°C/75%RH. Each condition had pull points at 0, 3, 6, 9, 12, 18, and 24 months, totaling over 60 data pulls per batch across three pilot-scale lots.

While comprehensive, the sponsor began to question whether all time points were necessary, especially considering the historical stability of the API and similar marketed formulations.

🔍 Problem Statement

Could the sponsor justify reducing some intermediate time points—particularly 9- and 18-month pulls—without regulatory pushback or risking patient safety?

This led to a structured Quality Risk Management (QRM) exercise based on ICH Q9 principles.

⚙️ Step 1: Cross-Functional QRM Team Formation

A cross-functional team was formed comprising representatives from:

• 👨‍🎓 Analytical Development
• 👪 Regulatory Affairs
• 🛠️ Quality Assurance
• 🧑‍🎓 Formulation Development

This ensured a balanced risk assessment with inputs from science, compliance, and business.

📈 Step 2: Data Mining and Knowledge Capture

The team collated historical data including:

• 📊 Forced degradation studies on the API
• 📊 Three years of ICH Zone IVb real-time data for similar products
• 📊 Literature on degradation kinetics for the compound class

None of the batches had shown degradation beyond 1% for assay, dissolution, or impurities across any condition up to 24 months. All OOS/OOT events were related to analytical variability rather than formulation performance.

📑 Step 3: Risk Identification and RPN Scoring

The team used a Failure Mode and Effects Analysis (FMEA) approach. Risk factors like temperature sensitivity, moisture ingress, and analytical variability were scored for Severity (S), Probability (P), and Detectability (D).

All critical degradation risks had RPNs below 10, indicating low risk. The only moderate RPN was analytical variability, which would be mitigated by increased system suitability checks.

📦 Step 4: Regulatory Precedents and Internal Alignment

The team searched GMP compliance databases and prior regulatory submissions and found multiple instances where reduced time points were accepted—especially when justified by sound science and supported by strong initial stability data.

After internal review, the proposal was updated to remove the 9-month and 18-month pulls at 30°C/65%RH while maintaining critical points like 0, 6, 12, and 24 months.

📑 Step 5: Protocol Amendment and Justification

Based on the QRM exercise, the protocol was revised to reflect a scientifically justified reduction of storage time points. The revised schedule included the following:

• ✅ 25°C/60%RH: 0, 3, 6, 12, 24 months
• ✅ 30°C/65%RH: 0, 6, 12, 24 months (removed 9 and 18 months)
• ✅ 40°C/75%RH: 0, 1, 2, 3, 6 months (remained unchanged)

The justification section of the amended protocol included:

• 📝 Historical data analysis summary
• 📝 FMEA matrix and RPN calculations
• 📝 Cross-reference to previous regulatory filings showing acceptance

This transparent documentation aligned with expectations from regulatory compliance reviewers and adhered to principles of Quality by Design (QbD).

💻 Step 6: Execution and Data Monitoring

Stability chambers were programmed according to the revised schedule. The first two data pulls (3 and 6 months) at 25°C/60%RH and 30°C/65%RH showed no trend of degradation, confirming the soundness of the reduced plan.

Data monitoring included:

• 📊 Trending reports using control charts for assay and impurities
• 📊 CAPA tracking system to flag any unexpected OOT/OOS values
• 📊 Periodic risk re-evaluation every 6 months

📊 Regulatory Feedback and Inspection Outcome

During a subsequent GMP inspection by a regulatory agency, the modified stability protocol was scrutinized. Inspectors were provided with the QRM justification, data summaries, and the amended protocol. The outcome:

• 🏆 No 483s issued
• 🏆 Verbal acknowledgment of strong QRM documentation
• 🏆 Suggestion to publish the approach as a best practice

The case demonstrated how scientifically sound decisions, when well documented, are not only acceptable but appreciated by regulators.

💡 Benefits Realized from Time Point Reduction

These results showcase how even minor protocol optimizations can lead to measurable savings and operational efficiency without compromising compliance or product safety.

🎯 Lessons Learned

• 📌 Historical data is a powerful tool when linked to scientific reasoning
• 📌 Cross-functional collaboration strengthens QRM implementation
• 📌 Regulators support rational reduction when presented transparently
• 📌 Risk scoring (e.g., FMEA) adds numerical weight to your case

⛽ Final Thoughts

This case illustrates how risk-based reduction of stability time points is not only feasible but also desirable in certain situations. By using ICH Q9 principles and proactively communicating with regulatory stakeholders, companies can streamline their stability programs while upholding quality standards.

To explore related case-based QRM strategies in equipment qualification, visit our resource on equipment qualification.